about
Past, present, and future of radiotherapy for the benefit of patients[Obesity and cancer].[Integrating patient education in your oncology practice].[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view].Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.[Big data and their perspectives in radiation therapy].[Indications and results for protontherapy in cancer treatments].[Renal involvement in cancer and renal paraneoplastic syndromes].Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study.Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Image-guided radiotherapy for cardiac sparing in patients with left-sided breast cancer.History of the rare cancer network and past research.Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].[Microscopic extensions of head and neck squamous cell carcinomas: impact for clinical target volume definition].Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.Combination of radiotherapy with EGFR antagonists for head and neck carcinoma.Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.Jugular Vein Invasion Diagnosis and Prognosis in Thyroid Carcinomas.Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.Need for neck dissection after radiochemotherapy? A study of the French GETTEC Group.Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?Qualitative ultrasound elastography assessment of benign thyroid nodules: Patterns and intra-observer acquisition variability.New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival?Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study.Reirradiation in head and neck cancers.Osteosarcomas of the mandible: are they different from other tumor sites?Image-guided radiation therapy for muscle-invasive bladder cancer.The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease.Not all sarcomas developed in irradiated tissue are necessarily radiation-induced--spectrum of disease and treatment characteristics.The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.Features of cancer management in obese patients.Treatment of cervical paragangliomas.Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.Chemoradiation in anaplastic thyroid carcinomas.Local ablative treatments of oligometastases from head and neck carcinomas.A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).
P50
Q28280008-930E0641-44D2-4097-975E-61536B6EACC4Q30239984-BE4E07A8-3E23-4314-ADF6-323E37847BFEQ30249692-135141E2-6BB2-4B9C-9855-BE9513C7068FQ30585579-38406BAA-E7A7-44D3-93E1-FD462FE62587Q30655673-B86C1FFC-A9DE-4CE9-AEFE-C05D2CCC1610Q31146722-179A350B-D202-43FC-A308-B6D82DE05C63Q33276198-C33E1CB7-6EA6-42FF-A518-895BD8E495B2Q33398613-56DA87AD-F93C-4845-BC4E-3F7043508073Q33729963-1BA1055A-3DC6-4F95-8BE1-5E797D7AC07CQ34015012-A222F3B2-E325-4660-8639-77F51989D9B4Q34106002-61EFB81D-1883-4549-8462-173375ADE639Q34216725-6949FFCE-8C8D-4B3C-B96C-A7F498A3B481Q34229813-BAFD4E7A-B50E-4E38-8C79-F965859AACDEQ34259200-B9E3E9B8-79F3-4EBE-8DAD-8F406D088CFDQ34299445-F776CBD0-9A25-4794-AD8B-E43AFD2294D1Q35017481-56CA728B-B733-43E1-88D4-7F23A2426742Q35198748-12E162C8-2FCD-493F-B6E7-04F7A0DD316FQ36175239-A5E6F510-3663-438E-826E-3EB453E47C68Q36795322-15EB92A5-BD43-48D0-B480-FA2A81BB9356Q36967766-D0052918-FAD1-431C-981B-2C2A272BA40EQ37003012-9BFD808D-0736-4C47-8F6A-17A168717847Q37072583-475E7F20-072A-4E95-A7B5-A00AA8F49A43Q37275282-798425EA-8F65-4C31-9E9A-D8AB0181CA1CQ37339684-E4301B9D-F96F-4CCD-8EAA-222B44C882D2Q37384166-9ED9ACAE-9809-4E86-B608-E67F07C58FACQ37599198-F47C1800-7A39-45B0-B7BE-68C7E3514B89Q37807250-3CC93F90-60B4-4C87-A3FB-9232C9B0D100Q37822609-B6A9AFA1-B0BC-41F5-96D3-355D2C453D5AQ37832635-A66D7959-9B3C-4C87-BB88-8811839EDE74Q37922390-23139D8E-3246-4E4A-A2AF-0653EA809496Q37953815-A5BE14B5-E282-407D-8280-DBE0922B2AE6Q37959114-48A15064-2F28-464C-954C-FBAC5207F05CQ37964344-33742B89-898C-41BA-94AB-220787D16BE3Q37990279-07585C45-0909-4736-B288-F693C6072FA1Q38024895-6539C3BE-3704-40DE-A5D4-C94821B0AC6CQ38047584-65DF106F-10A8-4CA6-B424-174FB3E0D14BQ38058168-EAF3BFB2-E9FC-40C2-B2B3-9263151D7010Q38065471-E6819AEC-3C33-486A-A887-E288196D7DF7Q38189946-1BB45805-4F12-4516-A6B6-7B452DF9A448Q38196550-D9110681-3EC7-4559-9550-98C7CD7174D2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juliette Thariat
@ast
Juliette Thariat
@en
Juliette Thariat
@es
Juliette Thariat
@nl
type
label
Juliette Thariat
@ast
Juliette Thariat
@en
Juliette Thariat
@es
Juliette Thariat
@nl
prefLabel
Juliette Thariat
@ast
Juliette Thariat
@en
Juliette Thariat
@es
Juliette Thariat
@nl
P106
P1153
16240019100
P31
P496
0000-0003-4755-496X